
|Videos|March 1, 2017
A Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer
Author(s)John Robertson, MD
John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant versus anastrozole in patients with HR-positive advanced breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































